Medical Device Manufacturing in European Union 2026: Industry Statistics & Trends

The medical device manufacturing industry in the European Union encompasses the design and production of a broad range of products, spanning from everyday consumables like bandages and syringes to high-tech diagnostic equipment and life-saving implantable devices. According to the industry association MedTech Europe, the European medical technology market reached an estimated valuation of 170 billion EUR in 2024, maintaining its position as the second-largest global market with a 26.4% market share (MedTech Europe Facts & Figures 2024). While demand remains stable due to aging demographics, the industry is navigating significant administrative and structural shifts as operators fully transit

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Medical Device Manufacturing in European Union industry cover?

The sector encompasses all economic entities involved in the research, development, and manufacturing of medical technologies and in vitro diagnostics (IVD). These technologies comprise more than 2 million unique products used throughout the continuum of care, from initial prevention and screening to active treatment and long-term disease management. The spectrum includes basic surgical supplies, orthopedic implants, cardiology pacemakers, medical imaging infrastructure, and digital health applications.

• •Encompasses both medical devices and in vitro diagnostic systems under distinct EU regulatory definitions.
• •Over 15,900 patent applications were filed with the European Patent Office (EPO) in medical technology in 2023, representing 8% of all filings.
• •Product lifecycles are exceptionally rapid, with improvements or new iterations arriving every 18 to 24 months on average.

Who operates in the industry and how is it structured?

The operational landscape within the European Union is structurally diverse, consisting of a vast network of enterprises that provide high-value industrial employment. Germany stands as the largest manufacturing hub and market, accounting for roughly 25.2% of the European market share, followed by France, Italy, and Spain. The workforce is characterized by high productivity, generating substantial value-added economic output per employee across individual member states.

• •The sector directly employs more than 880,000 individuals across Europe, with the highest absolute employment concentrated in Germany.
• •The industry is highly fragmented, featuring more than 38,000 medical technology companies operating within Europe.
• •Small and medium-sized enterprises (SMEs) dominate the operational fabric, constituting 90% of all sector entities.

What drives demand in the industry?

Demand is heavily insulated from short-term macroeconomic volatility due to fundamental demographic shifts and the non-discretionary nature of healthcare procurement. An aging European populace and the escalating prevalence of complex chronic illnesses create long-term requirements for diagnostic and therapeutic materials. Additionally, European public healthcare systems are increasingly leaning on digital health and remote monitoring solutions to enhance clinical efficiencies and manage cost burdens.

• •An estimated 60 million people across Europe live with diabetes, a key driver for continuous glucose monitors and metabolic management tools.
• •Average global research and development reinvestment sits at approximately 8% of total sales to meet clinical demands.
• •Cardiology, in vitro diagnostics, and diagnostic imaging represent the three largest global therapy sub-sectors.

Who are the notable companies in the industry?

The European marketplace features intense competition among homegrown regional champions, specialized mid-market developers, and massive multinational corporations with substantial localized production and R&D facilities. These market entities frequently engage in collaborative partnerships, strategic site expansions, and asset acquisitions to capture emerging medical fields such as robotic surgery and artificial intelligence-assisted diagnostics.

• •Siemens Healthineers AG remains a dominant European player, expanding its portfolio with point-of-care platforms like the Atellica DCA Analyser.
• •Koninklijke Philips N.V. is heavily invested in digital clinical solutions, partnering with entities like Sim&Cure to innovate neurovascular therapy.
• •F. Hoffmann-La Roche Ltd continues to expand its central laboratory diagnostic offerings, securing CE approvals for its cobas 6800/8800 systems.
• •Abbott Laboratories contributes significantly to EU manufacturing infrastructure, investing in a major facility in Kilkenny, Ireland in 2024.

What are the recent trends and outlook?

The European medical device ecosystem is executing a pivot toward breakthrough, digitally integrated platforms rather than simple iterative design updates. This evolution incorporates cloud-connected patient systems and machine-learning diagnostic tools to alleviate systemic strains on clinical personnel. However, manufacturers are balancing innovation pipelines against portfolio consolidations driven by structural shifts and certification timelines.

• •Average historical market growth in Europe has hovered around 5.4% annually over the past decade.
• •Industry margins face ongoing pressures from elevated compliance costs, affecting low-volume niche portfolios the most.
• •Supply continuity risks have prompted a notable volume of companies to transition or discontinue older legacy device lines.

How is the industry regulated?

Compliance within the EU is strictly dictated by centralized frameworks intended to ensure total consumer safety, clinical efficacy, and tracing capabilities across a device's entire lifecycle. The ongoing roll-out of updated frameworks has created substantial operational demands on manufacturers, who must engage deeply with third-party audited bodies. The systemic pressures have led trade groups and legislative authorities to seek balanced oversight adjustments that protect clinical access without stifling industrial agility.

• •The market is fundamentally governed by the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Medical Devices Regulation (IVDR).
• •The European Commission's 2025 Economic Operator Survey noted persistent administrative bottlenecks and review delays across notified bodies.
• •Products must satisfy rigorous quality management system (QMS) and clinical evidence benchmarks to successfully carry the mandatory CE mark.

Government, statistical and trade sources used for this Claight analysis.

• MedTech Europe Facts & Figures 2024 ·
• European Commission 2025 Survey on Medical Device Availability